Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2012

View Archived Issues

Meningitis B vaccine is immunogenic in adolescents in phase IIb/III trial

Novel dual modulators of serotonin 5-HT2A and dopamine D3 receptors reported

Idera Pharmaceuticals reports phase Ib data on IMO-2055

Chiesi Farmaceutici patents new muscarinic acetylcholine M receptor antagonists

Everolimus improves survival of patients with gastrointestinal cancer

FDA lifts clinical hold placed on Arikace program

Traditional medicine ameliorates chemotherapy-induced nausea and vomiting

Novel constrained vaccines created in Australia

CHMP issues opinion on Folotyn

Capstone Therapeutics terminates development of two products

New statin derivatives reported by NicOx

Medicago expands on rabies vaccine development

Novartis announces CHMP opinion on Signifor

Novel glucagon analogues described

Sandoz begins two phase III trials of biosimilars

Novel GlyT-1 inhibitors reported by Roche

MEK-162 investigated in biliary tract cancer

Enrollment opens in phase III PRESENT study of NeuVax

Intravenous Bonalon approved in Japan

EMA reviews Gilenya following reports of heart problems in patients

OncoSec Medical updates corporate progress

EMA recommends marketing suspension for meprobamate-containing medicines

FDA committee against approval of vaginal gel to reduce preterm birth

FDA offers guidance on EpiCept's AmiKet program

Study investigates tasquinimod/cabazitaxel combination in prostate cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...